SAN FRANCISCO, CA—The Gladstone Institutes and the international pharmaceutical company H. Lundbeck A/S have announced a collaborative research agreement to study and identify therapeutic candidates for neurological diseases.
SAN FRANCISCO, CA—Scientists at the Gladstone Institute of Neurological Disease (GIND) and Stanford University have shown how key circuits in the brain control movement.
SAN FRANCISCO, CA—Stimulating the growth of new neurons to replace those lost in Alzheimer's disease (AD) is an intriguing therapeutic possibility. But will the factors that cause AD allow the new neurons to thrive and function normally?
SAN FRANCISCO, CA—The J. David Gladstone Institutes announced that it has received a major grant from the W.M. Keck Foundation in Los Angeles to establish the Keck Program for Striatal Physiology and Pathophysiology, which will study the origins of movement disorders associated with neurological diseases such as Parkinson's and Huntington's diseases.
SAN FRANCISCO, CA—Scientists from the Gladstone Institute of Neurological Disease (GIND), UCSF, and Stanford have discovered that a certain type of collagen, collagen VI, protects brain cells against amyloid-beta (Aβ) proteins, which are widely thought to cause Alzheimer's disease.